Fundraising Fox
Mustang Bio
NASDAQ: MBIOWorcester, US · Delaware corporation · 42 employees on LinkedIn · 1 known investors
Find your way into Mustang Bio
Sign up to see every warm intro you have to Mustang Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mustang Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.
Founders & leadership
MW
Michael WeissExecutive
ML
Manuel LitchmanPresident, Chief Executive Officer and DirectorManuel Litchman is President and CEO of Mustang Bio, a clinical-stage biopharmaceutical company developing CAR-T and oncolytic virus therapies. He holds a background as a clinical hematologist-oncologist and has over 30 years of experience in pharmaceutical and biotech, including prior leadership roles at Roche, Novartis, and Arvinas where he contributed to the development of approved CAR T therapies.
GF
Greg FurrowChief Quality OfficerGreg Furrow has over 20 years of experience in pharmaceutical and biologics quality assurance, regulatory compliance, and manufacturing operations. He currently serves as Chief Quality Officer at Mustang Bio, where he oversees CMC functions and CAR-T cell therapy manufacturing and quality assurance.
Board
LA
Lindsay A. RosenwaldBoard director
NH
Neil HerskowitzBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$102.3M disclosed across 4 rounds · 2017–2024
▶$2.5MraisedJun 2024 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manuel B. Litchman, M.D.Executive Officer, Director
- Adam J. ChillDirector
- Michael Zelefsky, M.D.Director
- James B MurphyExecutive Officer
- Neil HerskowitzDirector
- Lindsay A. Rosenwald, M.D.Director
- Michael S. WeissDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $175.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedNov 2023 · 1 investors · BiotechnologyRule 506(b)
▶$4.7MraisedNov 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam J. ChillDirector
- Michael WeissDirector
- Manuel S. Litchman, M.D.Executive Officer, Director
- Lindsay A. Rosenwald, M.D.Director
- Michael Zelefsky, M.D.Director
- Neil HerskowitzDirector
- Eliot LurierExecutive Officer
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- Sales commissions
- $308K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$416KraisedApr 2017 · 7 investors · BiotechnologyRule 506(b)
▶$416KraisedApr 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael S. WeissExecutive Officer, Director
- Neil HerskowitzDirector
- Lindsay A. RosenwaldDirector
- Offering amount
- $416K
- Amount sold
- $416K
- Sales commissions
- $45.6K
- Placement agents
- National Securities Corporation
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$94.6MraisedFeb 2017 · 1086 investors · BiotechnologyRule 506(b)
▶$94.6MraisedFeb 2017 · 1086 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael S. WeissExecutive Officer, Director
- Neil HerskowitzDirector
- Lindsay A. RosenwaldDirector
- Offering amount
- $100M
- Amount sold
- $94.6M
- Sales commissions
- $9.5M
- Placement agents
- National Securities Corporation
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Mammoth BiosciencesMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies working in the same space as Mustang Bio.
Frequently asked questions
- What does Mustang Bio do?
- Mustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.
- Who are Mustang Bio's investors?
- Mustang Bio's investors include Runway Growth Capital.
- How much funding has Mustang Bio raised?
- Mustang Bio has disclosed $102.3M raised across 4 rounds.
- Where is Mustang Bio headquartered?
- Mustang Bio is headquartered in Worcester, US.